MariMed Q3 revenue rises as market share of branded products grows
MRMD•MariMed’s third-quarter revenue rose 8.5% year over year to $44.2 million, while adjusted EBITDA increased 18% sequentially to $4.7 million. Net loss widened year over year to $3.5 million.
1. Revenue and earnings
MariMed reported third-quarter revenue of $44.2 million, up 8.5% year over year and above the $41.2 million consensus estimate. Adjusted EBITDA was $4.7 million, up 18% sequentially and above the $4.3 million estimate; net loss widened year over year to $3.5 million.
2. Sales and margins
The company said higher wholesale and retail sales and increased market share for branded products, including Betty’s Eddies and other top-10 brands, contributed to revenue growth. Higher transactions and average order value at Thrive retail stores helped drive retail revenue growth. Gross margin was 38.8%, with the company citing continued wholesale price compression for the year-over-year decline.
3. Company priorities
MariMed said its focus for the fourth quarter and 2027 is growing market share and opening new accounts. It also said it will monitor federal cannabis reform and possible tax and banking changes.
